Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate

NCT00225420 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT00225420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00225420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2005
Completion date
August 31, 2012
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer